Evolution of Lesion Formation, Parasitic Load, Immune Response, and Reservoir Potential in C57BL/6 Mice following High- and Low-Dose Challenge withLeishmania major
Open Access
- 1 September 2000
- journal article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 68 (9) , 5176-5182
- https://doi.org/10.1128/iai.68.9.5176-5182.2000
Abstract
A model of cutaneous leishmaniasis using 102 Leishmania major metacyclic promastigotes inoculated into the footpads of genetically resistant C57BL/6 mice was studied in order to more accurately reproduce the evolution of lesion formation and the kinetics of parasite growth and immune response as they might occur in naturally exposed reservoirs and in human hosts. In contrast to the more conventional experimental model employing 106metacyclic promastigotes, in which the rapid development of footpad lesions was associated with an increasing number of amastigotes in the site, the low-dose model revealed a remarkably “silent” phase of parasite growth, lasting approximately 6 weeks, during which peak parasitic loads were established in the absence of any overt pathology. Footpad swelling was observed after 6 weeks, coincident with the onset of parasite clearance and with production of high levels of interleukin-12 (IL-12) and gamma interferon (IFN-γ) in draining lymph nodes. Low-dose challenge of IL-12- and IFN-γ-depleted or -deficient mice provided strong evidence that the induction or expression of cellular immunity is essentially absent during the first 6 to 8 weeks of intracellular growth, since the concentration of amastigotes in the site was not enhanced compared to that for wild-type animals during this time. By monitoring the ability of infected mice to transmit parasites to vector sand flies, it was observed that following low-dose challenge, footpads without apparent lesions provided an efficient source of parasites for exposed flies and that the low-dose challenge actually extended the duration of parasite transmissibility during the course of infection.Keywords
This publication has 45 references indexed in Scilit:
- Parasite dose determines the Th1/Th2 nature of the response toLeishmania major independently of infection route and strain of host or parasiteEuropean Journal of Immunology, 1998
- Leishmania promastigotes selectively inhibit interleukin 12 induction in bone marrow-derived macrophages from susceptible and resistant mice.The Journal of Experimental Medicine, 1996
- Infection with Leishmania major induces interleukin-12 production in vivoImmunology Letters, 1994
- Leishmania promastigotes evade interleukin 12 (IL-12) induction by macrophages and stimulate a broad range of cytokines from CD4+ T cells during initiation of infection.The Journal of Experimental Medicine, 1994
- Langerhans cells transport Leishmania major from the infected skin to the draining lymph node for presentation to antigen‐specific T cellsEuropean Journal of Immunology, 1993
- Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response.The Journal of Experimental Medicine, 1993
- Recombinant interleukin 12 cures mice infected with Leishmania major.The Journal of Experimental Medicine, 1993
- Establishment of Stable, Cell-Mediated Immunity that Makes "Susceptible" Mice Resistant to Leishmania majorScience, 1992
- Salivary Gland Lysates from the Sand Fly Lutzomyia longipalpis Enhance Leishmania InfectivityScience, 1988
- A limiting dilution assay for quantifying Leishmania major in tissues of infected miceParasite Immunology, 1985